Synthetic oligodeoxynucleotides containing multiple telemeric TTAGGG motifs suppress inflammasome activity in macrophages subjected to oxygen and glucose deprivation and reduce ischemic brain injury in stroke-prone spontaneously hypertensive rats

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Zhao, Jing ^a,b   Mou, Yongshan ^b   Bernstock, Joshua D ^b   Klimanis, Dace ^b   Wang, Sixian ^c   Spatz, Maria ^b   Maric, Dragan ^b   Johnson, Kory ^b   Klinman, Dennis M ^d   Li, Xiaohong ^a   Li, Xinhui ^b   Hallenbeck, John M ^b  

^a JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c Department of Molecular Biology and Genetics   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 151; ANTIINFLAMMATORY AGENT; CRYOPYRIN; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; OXYGEN; POLYPEPTIDE; THREONYLTHREONYLALANYLGLYCYLGLYCYLGLYCINE; UNCLASSIFIED DRUG; CARRIER PROTEIN; CPG-OLIGONUCLEOTIDE; IL1B PROTEIN, RAT; NLRP3 PROTEIN, RAT; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN ISCHEMIA; CELL MEMBRANE DEPOLARIZATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; MACROPHAGE ACTIVATION; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROMODULATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN SYNTHESIS INHIBITION; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; IMMUNOLOGY; MACROPHAGE; METABOLISM; NUCLEOTIDE MOTIF; PATHOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; TELOMERE;

ANIMALS; BRAIN ISCHEMIA; CARRIER PROTEINS; CASPASE 1; GLUCOSE; INFLAMMASOMES; INTERLEUKIN-1BETA; MACROPHAGES; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; NUCLEOTIDE MOTIFS; OLIGODEOXYRIBONUCLEOTIDES; OXYGEN; RATS; RATS, INBRED SHR; TELOMERE;

EID: 84949217687     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140772     Document Type: Article

References (85)

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, et al. (2014) Globaland regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 383: 245-254. PMID: 24449944
2. Trott DW, Harrison DG (2014) The immune system in hypertension. Adv Physiol Educ 38: 20-24. doi: 10.1152/advan.00063.2013 PMID: 24585465
3. Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12: 204-212. doi: 10.1038/ni.2001 PMID: 21321594
4. Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358: 221-229. PMID: 11476858
5. Seijkens T, Kusters P, Chatzigeorgiou A, Chavakis T, Lutgens E (2014) Immune cell crosstalk in obesity: a key role for costimulation? Diabetes 63: 3982-3991. doi: 10.2337/db14-0272 PMID: 25414012
6. Guo Y, Lip GY, Apostolakis S (2012) Inflammation in atrial fibrillation. J Am Coll Cardiol 60: 2263-2270. doi: 10.1016/j.jacc.2012.04.063 PMID: 23194937
7. Mazzone P, Tierney W, Hossain M, Puvenna V, Janigro D, et al. (2010) Pathophysiological impact of cigarette smoke exposure on the cerebrovascular system with a focus on the blood-brain barrier: expanding the awareness of smoking toxicity in an underappreciated area. Int J Environ Res Public Health 7: 4111-4126. doi: 10.3390/ijerph7124111 PMID: 21317997
8. Iadecola C, Anrather J (2011) The immunology of stroke: from mechanisms to translation. Nat Med 17: 796-808. doi: 10.1038/nm.2399 PMID: 21738161
9. Fang H, Wang PF, Zhou Y, Wang YC, Yang QW (2013) Toll-like receptor 4 signaling in intracerebral hemorrhage-induced inflammation and injury. J Neuroinflammation 10: 27. doi: 10.1186/1742-2094-10-27 PMID: 23414417
10. Saver JL (2011) Improving reperfusion therapy for acute ischaemic stroke. JThromb Haemost 9 Suppl 1: 333-343. doi: 10.1111/j.1538-7836.2011.04371.x PMID: 21781270
11. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, et al. (2006) 1, 026 experimental treatments in acute stroke. Ann Neurol 59: 467-477. PMID: 16453316
12. Latz E, Xiao TS, Stutz A (2013) Activation and regulation of the inflammasomes. Nat Rev Immunol 13: 397-411. doi: 10.1038/nri3452 PMID: 23702978
13. Schroder K, Tschopp J (2010) The inflammasomes. Cell 140: 821-832. doi: 10.1016/j.cell.2010.01. 040 PMID: 20303873
14. Dinarello CA (2011) A clinical perspective of IL-1betaas the gatekeeper of inflammation. EurJ Immunol 41:1203-1217. doi: 10.1002/eji.201141550 PMID: 21523780
15. Bergsbaken T, Fink SL, Cookson BT (2009) Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 7: 99-109. doi: 10.1038/nrmicro2070 PMID: 19148178
16. Denes A, Lopez-Castejon G, Brough D (2012)Caspase-1: is IL-1 justthetipofthe ICEberg?Cell Death Dis 3: e338. doi: 10.1038/cddis.2012.86 PMID: 22764097
17. Lambertsen KL, Biber K, Finsen B (2012) Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 32:1677-1698. doi: 10.1038/jcbfm.2012.88 PMID: 22739623
18. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, et al. (1995) Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 26:1393-1398. PMID: 7631343
19. Sotgiu S, Zanda B, Marchetti B, Fois ML, Arru G, et al. (2006) Inflammatory biomarkers in blood of patients with acute brain ischemia. EurJ Neurol 13: 505-513. PMID: 16722977
20. Mazzotta G, Sarchielli P, Caso V, Paciaroni M, Floridi A, et al. (2004) Different cytokine levels in thrombolysis patients as predictors for clinical outcome. EurJ Neurol 11:377-381. PMID: 15171733
21. Benchoua A, Braudeau J, Reis A, Couriaud C, Onteniente B (2004) Activation of proinflammatory cas-pases by cathepsin B in focal cerebral ischemia. J Cereb Blood Flow Metab 24:1272-1279. PMID: 15545923
22. Deroide N, Li X, Lerouet D, Van Vre E, Baker L, et al. (2013) MFGE8 inhibits inflammasome-induced IL-1beta production and limits postischemic cerebral injury. J Clin Invest 123:1176-1181. doi: 10.1172/JCI65167 PMID: 23454767
23. Abulafia DP, de Rivero Vaccari JP, Lozano JD, Lotocki G, Keane RW, et al. (2009) Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice. J Cereb Blood Flow Metab 29: 534-544. doi: 10.1038/jcbfm.2008.143 PMID: 19066616
24. Fann DY, Lee SY, Manzanero S, Tang SC, Gelderblom M, et al. (2013) Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis 4: e790. doi: 10.1038/cddis.2013.326 PMID: 24008734
25. Zhang N, Zhang X, Liu X, Wang H, Xue J, et al. (2014)Chrysophanol inhibits NALP3 inflammasome activation and ameliorates cerebral ischemia/reperfusion in mice. Mediators Inflamm 2014: 370530. doi: 10.1155/2014/370530 PMID: 24876671
26. Shampay J, Szostak JW, Blackburn EH (1984) DNA sequences of telomeres maintained in yeast. Nature 310:154-157. PMID: 6330571
27. Meyne J, Ratliff RL, Moyzis RK (1989) Conservation of the human telomere sequence (TTAGGG)n among vertebrates. Proc Natl Acad Sci U S A 86: 7049-7053. PMID: 2780561
28. Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, et al. (2003) Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol 171:1393-1400. PMID: 12874230
29. Yamada H, Ishii KJ, Klinman DM (2004) Suppressive oligodeoxynucleotides inhibit CpG-induced inflammation of the mouse lung. CritCare Med 32: 2045-2049. PMID: 15483413
30. Shirota H, Gursel M, Klinman DM (2004) Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma-and IL-12-mediated signaling. J Immunol 173: 5002-5007. PMID: 15470043
31. Shirota H, Gursel I, Gursel M, Klinman DM (2005) Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol 174: 4579-4583. PMID: 15814679
32. Zeuner RA, Verthelyi D, Gursel M, Ishii KJ, Klinman DM (2003) Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum 48:1701-1707. PMID: 12794839
33. Li N, Liu YH, Li SL, Fu CY, Zhou RR, et al. (2013) Protective role of synthetic oligodeoxynucleotides expressing immunosuppressive TTAGGG motifs in concanavalin A-induced hepatitis. Immunol Lett 151: 54-60. doi: 10.1016/j.imlet.2013.02.004 PMID: 23470496
34. Fujimoto C, Klinman DM, Shi G, Yin H, Vistica BP, et al. (2009) A suppressive oligodeoxynucleotide inhibits ocular inflammation. Clin Exp Immunol 156: 528-534. doi: 10.1111/j.1365-2249.2009.03918.x PMID: 19438607
35. Dong L, Ito S, Ishii KJ, Klinman DM (2005) Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZBx NZW mice. Arthritis Rheum 52: 651-658. PMID: 15692999
36. Cheng X, Chen Y, Xie JJ, Yao R, Yu X, et al. (2008) Suppressive oligodeoxynucleotides inhibit atherosclerosis in ApoE(-/-) mice through modulation of Th1/Th2 balance. J Mol Cell Cardiol 45:168-175. doi: 10.1016/j.yjmcc.2008.04.003 PMID: 18502445
37. Sato T, Shimosato T, Alvord WG, Klinman DM (2008) Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation. J Immunol 180: 7648-7654. PMID: 18490767
38. Jahrsdorfer B, Weiner GJ (2008) CpG oligodeoxynucleotides as immunotherapy in cancer. Update CancerTher 3: 27-32. PMID: 19255607
39. Bedikian AY, Garbe C, Conry R, Lebbe C, Grob JJ, et al. (2014) Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'. Melanoma Res 24: 237-243. doi: 10.1097/CMR.0000000000000056 PMID: 24667300
40. Koo T, Wood MJ (2013) Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. Hum Gene Ther 24: 479-488. doi: 10.1089/hum.2012.234 PMID: 23521559
41. Chiba T, Umegaki K(2013) Pivotal roles of monocytes/macrophages in stroke. Mediators Inflamm 2013: 759103. doi: 10.1155/2013/759103 PMID: 23431245
42. Davis BK (2013) Isolation, culture, and functional evaluation of bone marrow-derived macrophages. Methods Mol Biol 1031: 27-35. doi: 10.1007/978-1-62703-481-4 3 PMID: 23824883
43. Westwell-Roper C, Dunne A, Kim ML, Verchere CB, Masters SL (2013) Activating the NLRP3 inflam-masome using the amyloidogenic peptide IAPP. Methods Mol Biol 1040: 9-18. doi: 10.1007/978-1-62703-523-1 2 PMID: 23852593
44. Hunter AJ, Hatcher J, Virley D, Nelson P, Irving E, et al. (2000) Functional assessments in mice and rats after focal stroke. Neuropharmacology 39:806-816. PMID: 10699446
45. Chen Y, Ruetzler C, Pandipati S, Spatz M, McCarron RM, et al. (2003) Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury. Proc Natl Acad Sci U S A 100:15107-15112. PMID: 14645708
46. Takahashi M (2011) Roleoftheinflammasomein myocardial infarction. Trends Cardiovasc Med 21: 37-41. doi: 10.1016/j.tcm.2012.02.002 PMID: 22578238
47. Sagulenko V, Thygesen SJ, Sester DP, Idris A, Cridland JA, et al. (2013) AIM2 and NLRP3 inflamma-somes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ 20:1149-1160. doi: 10.1038/cdd.2013.37 PMID: 23645208
48. Kim YJ, Hwang SY, Oh ES, Oh S, Han IO (2006) IL-1beta, an immediate early protein secreted by activated microglia, induces iNOS/NO in C6 astrocytoma cells through p38 MAPK and NF-kappaB pathways. J Neurosci Res 84:1037-1046. PMID: 16881054
49. Iadecola C, Zhang F, Casey R, Clark HB, Ross ME (1996) Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke 27:1373-1380. PMID: 8711805
50. Elliott EI, Sutterwala FS (2015) Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev 265: 35-52. doi: 10.1111/imr.12286 PMID: 25879282
51. Fugate JE, Lyons JL, Thakur KT, Smith BR, Hedley-Whyte ET, et al. (2014) Infectious causes of stroke. Lancet Infect Dis 14: 869-880. doi: 10.1016/S1473-3099(14)70755-8 PMID: 24881525
52. Emsley HC, Tyrrell PJ (2002) Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab 22:1399-1419. PMID: 12468886
53. Courties G, Moskowitz MA, Nahrendorf M (2014) The innate immune system after ischemic injury: lessons to be learned from the heart and brain. JAMA Neurol 71: 233-236. doi: 10.1001/jamaneurol. 2013.5026 PMID: 24296962
54. Emsley HC, Hopkins SJ (2008) Acute ischaemic stroke and infection: recent and emerging concepts. Lancet Neurol 7: 341-353. doi: 10.1016/S1474-4422(08)70061-9 PMID: 18339349
55. McColl BW, Allan SM, Rothwell NJ (2009) Systemic infection, inflammation and acute ischemic stroke. Neuroscience 158:1049-1061. doi: 10.1016/j.neuroscience.2008.08.019 PMID: 18789376
56. Henao-Mejia J, Elinav E, Strowig T, Flavell RA (2012) Inflammasomes: far beyond inflammation. Nat Immunol 13: 321-324. doi: 10.1038/ni.2257 PMID: 22430784
57. Davis BK, Wen H, TingJP (2011) The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29: 707-735. doi: 10.1146/annurev-immunol-031210-101405 PMID: 21219188
58. Walsh JG, Muruve DA, Power C (2014) Inflammasomes in the CNS. Nat Rev Neurosci 15: 84-97. doi: 10.1038/nrn3638 PMID: 24399084
59. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, et al. (2009) Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A 106: 20388-20393. doi: 10.1073/pnas.0908698106 PMID: 19918053
60. Broz P, von Moltke J, Jones JW, Vance RE, MonackDM (2010) Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host Microbe 8: 471-483. doi: 10.1016/j.chom.2010.11.007 PMID: 21147462
61. Satoh T, Kambe N, Matsue H (2013) NLRP3 activation induces ASC-dependent programmed necrotic cell death, which leads to neutrophilic inflammation. Cell Death Dis 4: e644. doi: 10.1038/cddis.2013. 169 PMID: 23703389
62. Fann DY, Santro T, Manzanero S, Widiapradja A, Cheng YL, et al. (2014) Intermittent fasting attenuates inflammasome activity in ischemic stroke. Exp Neurol 257:114-119. doi: 10.1016/j.expneurol. 2014.04.017 PMID: 24805069
63. Denes A, Coutts G, Lenart N, Cruickshank SM, Pelegrin P, et al. (2015) AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3. Proc Natl Acad Sci U S A 112: 4050-4055. doi: 10.1073/pnas.1419090112 PMID: 25775556
64. Kastbom A, Arlestig L, Rantapaa-Dahlqvist S (2015) Genetic Variants of the NLRP3 Inflammasome Are Associated with Stroke in Patients with Rheumatoid Arthritis. J Rheumatol.
65. Gurung P, Lukens JR, KannegantiTD (2015) Mitochondria: diversity in the regulation of the NLRP3 inflammasome. Trends Mol Med 21:193-201. doi: 10.1016/j.molmed.2014.11.008 PMID: 25500014
66. Zhou R, Yazdi AS, Menu P, Tschopp J (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469: 221-225. doi: 10.1038/nature09663 PMID: 21124315
67. Heid ME, Keyel PA, Kamga C, Shiva S, Watkins SC, et al. (2013) Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. J Immunol 191: 5230-5238. doi: 10.4049/jimmunol.1301490 PMID: 24089192
68. Chang YP, Ka SM, Hsu WH, Chen A, Chao LK, et al. (2015) Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy. J Cell Physiol 230:1567-1579. doi: 10.1002/jcp.24903 PMID: 25535911
69. Tannahill GM, Iraci N, Gaude E, Frezza C, Pluchino S (2015) Metabolic reprograming of mononuclear phagocytes in progressive multiple sclerosis. Front Immunol 6:106. doi: 10.3389/fimmu.2015.00106 PMID: 25814990
70. Kaminski JJ, Schattgen SA, Tzeng TC, Bode C, Klinman DM, et al. (2013) Synthetic oligodeoxynucleo-tides containing suppressive TTAGGG motifs inhibit AIM2 inflammasome activation. J Immunol 191: 3876-3883. doi: 10.4049/jimmunol.1300530 PMID: 23986531
71. Bode C, Wang J, Klinman DM (2014) Suppressive oligodeoxynucleotides promote the generation of regulatory T cells by inhibiting STAT1 phosphorylation. Int Immunopharmacol 23: 516-522. doi: 10. 1016/j.intimp.2014.09.027 PMID: 25311665
72. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, et al. (2009) Regulatory Tcells are key cere-broprotective immunomodulators in acute experimental stroke. Nat Med 15:192-199. doi: 10.1038/nm.1927 PMID: 19169263
73. Lim SY, Hausenloy DJ (2012) Remote ischemic conditioning: from bench to bedside. Front Physiol 3: 27. doi: 10.3389/fphys.2012.00027 PMID: 22363297
74. Peng B, Andrews J, Nestorov I, Brennan B, Nicklin P, et al. (2001) Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Anti-sense Nucleic Acid Drug Dev 11:15-27. PMID: 11258618
75. Saijo Y, Perlaky L, Wang H, Busch H (1994) Pharmacokinetics, tissue distribution, and stability of anti-sense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol Res 6: 243-249. PMID: 7865900
76. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, et al. (1995) Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 49: 929-939. PMID: 7741765
77. Wilson A, Zhou W, Champion HC, Alber S, Tang ZL, et al. (2005) Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. MolTher 12: 510-518. PMID: 15953766
78. Bijsterbosch MK, Manoharan M, Rump ET, De Vrueh RL, van Veghel R, et al. (1997) In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 25: 3290-3296. PMID: 9241243
79. Klinman DM (2004) Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4: 249-258. PMID: 15057783
80. Shirota H, Klinman DM (2014) Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines 13: 299-312. doi: 10.1586/14760584.2014.863715 PMID: 24308579
81. Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, et al. (2008) Toll-like receptor 9: a new target of ischemic preconditioning in the brain. J Cereb Blood FlowMetab 28:1040-1047. doi: 10.1038/sj. jcbfm.9600606 PMID: 18183029
82. Bahjat FR, Williams-Karnesky RL, Kohama SG, West GA, Doyle KP, et al. (2011) Proof of concept: pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury in a primate model of stroke. J Cereb Blood Flow Metab 31:1229-1242. doi: 10.1038/jcbfm. 2011.6 PMID: 21285967
83. Klinman DM, Tross D, Klaschik S, Shirota H, Sato T (2009) Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Ann NY Acad Sci 1175: 80-88. doi:1111/j.1749-6632.2009.04970.x PMID: 19796080
84. Klinman DM (2015) Therapeutic implications of orally delivered immunomodulatory oligonucleotides. Mol Ther 23: 222-223. doi: 10.1038/mt.2014.251 PMID: 25633172
85. Bode C, Yang XP, Kiu H, Klinman DM (2013) Suppressive oligodeoxynucleotides promote the development of Th17 cells. PLoSOne 8: e67991. doi: 10.1371/journal.pone.0067991 PMID: 23844143